
    
      Phase 2, multi-center, open label, single arm study to evaluate the effect and safety of
      ALLN-177 in adult and pediatric patients aged 12 and older with enteric hyperoxaluria and
      hyperoxalemia or primary hyperoxaluria .

      Approximately 15-20 evaluable subjects are planned to be enrolled in the study. Eligible
      subjects will administer ALLN-177 with each meal/snack 5 times per day for 12 consecutive
      weeks.
    
  